Therapeutic Efficacy of Platinum Based Medicines Combined with Various Nanoparticles in the Treatment of Colorectal Cancer: A Comprehensive Review
DOI:
https://doi.org/10.62382/jcbt.v2i1.32Keywords:
Colorectal cancer, Platinum-based chemotherapy, Nanoparticles, Drug delivery, Combination therapyAbstract
Colorectal cancer continues to be a major cancer that affects patients in terms of morbidity and mortality. Chemotherapy using cisplatin, oxaliplatin among others based with platinum have remained the mainstay in the treatment of diverse cancer including the colorectal cancer. However, these treatments are not very effective because of drug resistance, systemic toxicity, and low selectivity. The advances in nanotechnology in the past years presented nanoparticles as potential drug delivery systems which provide sharp targeting, minimum toxicity and better therapeutic efficacy. This review aims at discussing how platinum-based drugs can complement nanoparticles, for example liposomes, dendrimers and gold nanoparticles for colorectal cancer treatment. This review, discussed how nanoparticles can improve the effectiveness of platinum drugs; present sample findings from preclinical and clinical research; and analyze the perspectives of such combinations for the current therapy shortcomings overcoming. Furthermore, authors have looked at the prospects and challenges of this relatively young branch of research and discuss the opportunities that can lie in personalized medicine concepts, as well as the further evolution of nanoparticles. The purpose of this review is to enhance the current knowledge of platinum-nanoparticle combinations and to outline its future directions for colorectal cancer treatment.
Downloads
References
Buyana B, Naki T, Alven S, Aderibigbe BA. Nanoparticles Loaded with Platinum Drugs for Colorectal Cancer Therapy. International Journal of Molecular Sciences. 2022, 23(19), 11261.
Mahaki H, Mansourian M, Meshkat Z, Avan A, Shafiee MH, et al. Nanoparticles Containing Oxaliplatin and the Treatment of Colorectal Cancer. Current Pharmaceutical Design. 2023, 29(38), 3018-3039.
Deng Z, Wang N, Ai F, Wang Z, Zhu G. Nanomaterial‐Mediated Platinum Drug‐Based Combinatorial Cancer Therapy. View. 2020, 2(1), 20200030.
Wahnou H, Liagre B, Sol V, Attar HE, Attar R, et al. Polyphenol-Based Nanoparticles: A Promising Frontier for Enhanced Colorectal Cancer Treatment. Cancers. 2023, 15(15), 3826.
Guo J, Yu Z, Das M, Huang L. Nano Codelivery of Oxaliplatin and Folinic Acid Achieves Synergistic Chemo-Immunotherapy with 5-Fluorouracil for Colorectal Cancer and Liver Metastasis. ACS Nano. 2020, 14(4), 5075-5089.
Yang CX, Xing L, Chang X, Zhou TJ, Bi YY, et al. Synergistic Platinum(II) Prodrug Nanoparticles for Enhanced Breast Cancer Therapy. Molecular Pharmaceutics. 2020, 17(4), 1300-1309.
Akbari V, Abedi A, Akbari A, Salehi R. The potential of nanomaterials for cancer treatment via immune modulation: A review. Biomedicine & Pharmacotherapy. 2020, 130, 110729.
Kumar A, Huo S, Zhang X, Liu J, Tan A, et al. Neuropilin-1-Targeted Gold Nanoparticles Enhance Therapeutic Efficacy of Platinum(IV) Drug for Prostate Cancer Treatment. ACS Nano. 2014, 8(5), 4205-4220.
Shi L, Hu Y, Lin A, Ma C, Zhang C, et al. Matrix Metalloproteinase Responsive Nanoparticles for Synergistic Treatment of Colorectal Cancer via Simultaneous Anti-Angiogenesis and Chemotherapy. Bioconjugate Chemistry. 2016, 27(12), 2943-2953.
Chen Y, Li N, Xu B, Wu M, Yan X, et al. Polymer-Based Nanoparticles for Chemo/Gene-Therapy: Evaluation of Their Therapeutic Efficacy and Toxicity Against Colorectal Carcinoma. Biomedicine & Pharmacotherapy. 2019, 118, 109257.
Wang Y, Ma J, Qiu T, Tang M, Zhang X, et al. In vitro and in vivo Combinatorial Anticancer Effects of Oxaliplatin- and Resveratrol-Loaded N,O-Carboxymethyl Chitosan Nanoparticles Against Colorectal Cancer. European Journal of Pharmaceutical Sciences. 2021, 163, 105864.
Fu B, Dang M, Tao J, Li Y, Tang Y. Mesoporous Platinum Nanoparticle-Based Nanoplatforms for Combined Chemo-Photothermal Breast Cancer Therapy. Journal of Colloid and Interface Science. 2020, 570, 197-204.
Gao X, Lei G, Wang B, Deng Z, Karges J, et al. Encapsulation of Platinum Prodrugs into PC7A Polymeric Nanoparticles Combined with Immune Checkpoint Inhibitors for Therapeutically Enhanced Multimodal Chemotherapy and Immunotherapy by Activation of the STING Pathway. Advanced Science. 2022, 10(4), e2205241.
Arango D, Wilson AJ, Shi Q, Corner GA, Arañes MJ, et al. Molecular Mechanisms of Action and Prediction of Response to Oxaliplatin in Colorectal Cancer Cells. British Journal of Cancer. 2004, 91(11), 1931-1946.
Berners-Price SJ, Ronconi L, Sadler PJ. Insights into the Mechanism of Action of Platinum Anticancer Drugs from Multinuclear NMR Spectroscopy. Progress in Nuclear Magnetic Resonance Spectroscopy. 2006, 49(1), 65-98.
Ma MZ, Chen G, Wang P, Lu WH, Zhu CF, et al. Inhibitor Sulfasalazine Sensitizes Colorectal Cancer to Cisplatin by a GSH-Dependent Mechanism. Cancer Letters. 2015, 368(1), 88-96.
Shao H, Bai YS. Mechanism of Platinum Resistance in Colorectal Carcinoma. Journal of International Oncology. 2008, 35(04), 306-308.
McWhinney SR, Goldberg RM, McLeod HL. Platinum Neurotoxicity Pharmacogenetics. Molecular Cancer Therapeutics. 2009, 8(1), 10-16.
Köberle B, Schoch S. Platinum Complexes in Colorectal Cancer and Other Solid Tumors. Cancers. 2021, 13(9), 2073.
Al-Khayal K, Vaali-Mohammed MA, Elwatidy M, Traiki TB, Al-Obeed O, et al. A novel coordination complex of platinum (PT) induces cell death in colorectal cancer by altering redox balance and modulating MAPK pathway. BMC Cancer. 2020, 20(1), 685.
Hato SV, Figdor CG, Takahashi S, Pen AE, Halilovic A, et al. Direct Inhibition of STAT Signaling by Platinum Drugs Contributes to Their Anti-Cancer Activity. Oncotarget. 2017, 8(33), 54434-54443.
Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer Nanomedicine: Progress, Challenges and Opportunities. Nature Reviews Cancer. 2016, 17(1), 20-37.
Srinivasarao M, Galliford CV, Low PS. Principles in the Design of Ligand-Targeted Cancer Therapeutics and Imaging Agents. Nature Reviews Drug Discovery. 2015, 14(3), 203-219.
Allen TM, Cullis PR. Liposomal Drug Delivery Systems: From Concept to Clinical Applications. Advanced Drug Delivery Reviews. 2013, 65(1), 36-48.
Barenholz Y. D. The First FDA-Approved Nano-Drug: Lessons Learned. Journal of Controlled Release. 2012, 160(2), 117-134.
Yu B, Wang Y, Bing T, Tang Y, Huang J, et al. Platinum Prodrug Nanoparticles with COX-2 Inhibition Amplify Pyroptosis for Enhanced Chemotherapy and Immune Activation of Pancreatic Cancer. Advanced Materials. 2024, 36(11), e2310456.
Chauhan A. Dendrimers for Drug Delivery. Molecules. 2018, 23(4), 938.
Gillies E, Frechet J. Dendrimers and Dendritic Polymers in Drug Delivery. Drug Discovery Today. 2005, 10(1), 35-43.
Kukowska-Latallo JF, Candido KA, Cao Z, Nigavekar SS, et al. Nanoparticle Targeting of Anticancer Drug Improves Therapeutic Response in Animal Model of Human Epithelial Cancer. Cancer Research. 2005, 65(12), 5317-5324.
Huang X, Jain PK, El-Sayed IH, El-Sayed MA. Gold Nanoparticles: Interesting Optical Properties and Recent Applications in Cancer Diagnostics and Therapy. Nanomedicine. 2007, 2(5), 681-693.
Jain PK, Huang X, El-Sayed IH, El-Sayed MA. Review of Some Interesting Surface Plasmon Resonance-Enhanced Properties of Noble Metal Nanoparticles and Their Applications to Biosystems. Plasmonics. 2007, 2(3), 107-118.
Dykman LA, Khlebtsov NG. Gold nanoparticles in biology and medicine: recent advances and prospects. Acta Naturae. 2011, 3(2), 34-55.
Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, et al. Nanocarriers as an Emerging Platform for Cancer Therapy. Nature Nanotechnology. 2007, 2(12), 751-760.
Davis ME, Chen Z, Shin DM. Nanoparticle Therapeutics: An Emerging Treatment Modality for Cancer. Nature Reviews Drug Discovery. 2008, 7(9), 771-782.
Torchilin VP. Multifunctional, Stimuli-Sensitive Nanoparticulate Systems for Drug Delivery. Nature Reviews Drug Discovery. 2014, 13(11), 813-827.
Theile D. Under-Reported Aspects of Platinum Drug Pharmacology. Molecules. 2017, 22(3), 382.
Oun R, Moussa YE, Wheate NJ. The Side Effects of Platinum-Based Chemotherapy Drugs: A Review for Chemists. Dalton Transactions. 2018, 47(19), 6645-6653.
Markman JL, Rekechenetskiy A, Holler E, Ljubimova JY. Nanomedicine Therapeutic Approaches to Overcome Cancer Drug Resistance. Advanced Drug Delivery Reviews. 2013, 65(13-14), 1866-1879.
Shen MF, Wang YS, Bing TJ, Tang YJ, Liu XY, et al. Alendronate Triggered Dual‐Cascade Targeting Prodrug Nanoparticles for Enhanced Tumor Penetration and STING Activation of Osteosarcoma. Advanced Functional Materials. 2023, 33, 2307013.
Matsumura Y, Maeda H. A New Concept for Macromolecular Therapeutics in Cancer Chemotherapy: Mechanism of Tumoritropic Accumulation of Proteins and the Antitumor Agent SMANCS. Cancer Research. 1986, 46(12 Pt 1), 6387-6392.
Nel A, Xia T, Mädler L, Li N. Toxic Potential of Materials at the Nanolevel. Science. 2006, 311(5761), 622-627.
Elsabahy M, Wooley KL. Design of Polymeric Nanoparticles for Biomedical Delivery Applications. Chemical Society Reviews. 2012, 41(7), 2545.
Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer Drug Resistance: An Evolving Paradigm. Nature Reviews Cancer, 2013, 13(10), 714-726.
Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of Pegylated Liposomal Doxorubicin. Clinical Pharmacokinetics. 2003, 42(5), 419-436.
Xu X, Ho W, Zhang X, Bertrand N, Farokhzad O. Cancer Nanomedicine: From Targeted Delivery to Combination Therapy. Trends in Molecular Medicine. 2015, 21(4), 223-232.
Abed A, Derakhshan M, Karimi M, Shirazinia M, Mahjoubin-Tehran M, et al. Platinum Nanoparticles in Biomedicine: Preparation, Anti-Cancer Activity, and Drug Delivery Vehicles. Frontiers in Pharmacology. 2022, 13, 797804.
Xie P, Wang Y, Wei D, Zhang L, Zhang B, et al. Nanoparticle-Based Drug Delivery Systems with Platinum Drugs for Overcoming Cancer Drug Resistance. Journal of Materials Chemistry B, 2021, 9(26), 5173-5194.
Liu W, Li X, Wang T, Xiong F, Sun C, et al. Platinum Drug‐Incorporating Polymeric Nanosystems for Precise Cancer Therapy. Small. 2023, 19(21), e2208241.
Wang Y, Xie H, Ying K, Xie B, Chen X, et al. Tuning the Efficacy of Esterase-Activatable Prodrug Nanoparticles for the Treatment of Colorectal Malignancies. Biomaterials. 2021, 270, 120705.
Zhou H, Meng Q, Li B, Liu Y, Li Z, et al. Supramolecular Combination Chemotherapy: Cucurbit[8]uril Complex Enhanced Platinum Drug Infiltration and Modified Nanomechanical Property of Colorectal Cancer Cells. Langmuir. 2022, 38(46), 14326-14334.
Saha S, Banskota S, Liu J, Zakharov N, Dzuricky M, et al. Genetically Engineered Nanoparticles of Asymmetric Triblock Polypeptide with a Platinum(IV) Cargo Outperforms a Platinum(II) Analog and Free Drug in a Murine Cancer Model. Nano Letters. 2022, 22(14), 5898-5908.
Xiong G, Huang D, Lu L, Luo X, Wang Y, et al. Near-Infrared-II Light Induced Mild Hyperthermia Activate Cisplatin-Artemisinin Nanoparticle for Enhanced Chemo/Chemodynamic Therapy and Immunotherapy. Small Methods. 2022, 6(9), e2200379.
Watermann A, Brieger J. Mesoporous Silica Nanoparticles as Drug Delivery Vehicles in Cancer. Nanomaterials. 2017, 7(7), 189.
Xiong X, Arvizo RR, Saha S, Robertson DJ, McMeekin S, et al. Sensitization of Ovarian Cancer Cells to Cisplatin by Gold Nanoparticles. Oncotarget. 2014, 5(15), 6453-6465.
Li JQ, Wang SL, Xu F, Liu ZY, Li R. Therapeutic Effectiveness of Slow-Release PLGA-Oxaliplatin Microsphere on Human Colorectal Tumor-Bearing Mice. Anti-Cancer Drugs. 2010, 21(6), 600-608.
Hassan MS, Awasthi N, Ponna S, Von Holzen U. Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety. Biomedicines. 2023, 11(7), 2000.
Stathopoulos GP, Boulikas T, Kourvetaris A, Stathopoulos J. Liposomal Oxaliplatin in the Treatment of Advanced Cancer: A Phase I Study. Anticancer Research. 2006, 26(2B), 1489-1494.
Sveen A, Kopetz S, Lothe RA. Biomarker-Guided Therapy for Colorectal Cancer: Strength in Complexity. Nature Reviews Clinical Oncology. 2019, 17(1), 11-32.
Li QH, Wang YZ, Tu J, Liu CW, Yuan YJ, et al. Anti-EGFR Therapy in Metastatic Colorectal Cancer: Mechanisms and Potential Regimens of Drug Resistance. Gastroenterology Report. 2020, 8(3), 179-191.
Knebel FH, Barber LJ, Newey A, Kleftogiannis D, Woolston A, et al. Circulating Tumour DNA Sequencing Identifies a Genetic Resistance-Gap in Colorectal Cancers with Acquired Resistance to EGFR-Antibodies and Chemotherapy. Cancers. 2020, 12(12), 3736.
Sahin IH, Klostergaard J. BRAF Mutations as Actionable Targets: A Paradigm Shift in the Management of Colorectal Cancer and Novel Avenues. JCO Oncology Practice. 2021, 17(12), 723-730.
Pabla N, Dong Z. Cisplatin Nephrotoxicity: Mechanisms and Renoprotective Strategies. Kidney International. 2008, 73(9), 994-1007.
Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, et al. Chemotherapy‐Induced Peripheral Neurotoxicity: A Critical Analysis. CA a Cancer Journal for Clinicians. 2013, 63(6), 419-437.
Rybak LP, Mukherjea D, Jajoo S, Ramkumar V. Cisplatin Ototoxicity and Protection: Clinical and Experimental Studies. The Tohoku Journal of Experimental Medicine. 2009, 219(3), 177-186.
Akbarali HI, Muchhala KH, Jessup DK, Cheatham S. Chemotherapy-Induced Gastrointestinal Toxicities. Advances in Cancer Research. 2022, 155, 131-166.
Kim K, Khang D. Past, Present, and Future of Anticancer Nanomedicine. International Journal of Nanomedicine. 2020, 15, 5719-5743.
Karmali PP, Simberg D. Interactions of Nanoparticles with Plasma Proteins: Implication on Clearance and Toxicity of Drug Delivery Systems. Expert Opinion on Drug Delivery. 2011, 8(3), 343-357.
Bahrami B, Hojjat-Farsangi M, Mohammadi H, Anvari E, Ghalamfarsa G, et al. Nanoparticles and Targeted Drug Delivery in Cancer Therapy. Immunology Letters. 2017, 190, 64-83.
Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and Challenges Towards Targeted Delivery of Cancer Therapeutics. Nature Communications. 2018, 9(1), 1410.
Karlovich CA, Williams PM. Clinical Applications of Next-Generation Sequencing in Precision Oncology. The Cancer Journal. 2019, 25(4), 264–271.
Al-Zoubi MS, Al-Zoubi RM. Nanomedicine Tactics in Cancer Treatment: Challenge and Hope. Critical Reviews in Oncology/Hematology. 2022, 174, 103677.
Linares J, Sallent-Aragay A, Badia-Ramentol J, Recort-Bascuas A, Méndez A, et al. Long-Term Platinum-Based Drug Accumulation in Cancer-Associated Fibroblasts Promotes Colorectal Cancer Progression and Resistance to Therapy. Nature Communications. 2023, 14(1), 746.
Zhang C, Xu C, Gao X, Yao Q. Platinum-Based Drugs for Cancer Therapy and Anti-Tumor Strategies. Theranostics. 2022, 12(5), 2115-2132.
Timar J, Hegedus B, Raso E. KRAS Mutation Testing of Colorectal Cancer for Anti-EGFR Therapy: Dogmas Versus Evidence. Current Cancer Drug Targets. 2010, 10(8), 813-823.
Sanz-Garcia E, Argiles G, Elez E, Tabernero J. BRAF Mutant Colorectal Cancer: Prognosis, Treatment, and New Perspectives. Annals of Oncology. 2017, 28(11), 2648-2657.
Ratovomanana T, Nicolle R, Cohen R, Diehl A, Siret A, et al. Prediction of Response to Immune Checkpoint Blockade in Patients with Metastatic Colorectal Cancer with Microsatellite Instability. Annals of Oncology. 2023, 34(8), 703-713.
Sartore-Bianchi A, Amatu A, Porcu L, Ghezzi S, Lonardi S, et al. HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. The Oncologist. 2019, 24(10), 1395-1402.
Bignucolo A, De Mattia E, Cecchin E, Roncato R, Toffoli G. Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment. International Journal of Molecular Sciences, 2017, 18(7), 1522.
Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticles. Proceedings of the National Academy of Sciences. 2008, 105, 17356-17361.
Russo V, Lallo E, Munnia A, Spedicato M, Messerini L, et al. Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis. Cancers. 2022, 14(16), 4012.
Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MP, et al. Nano based drug delivery systems: recent developments and future prospects. Journal of Nanobiotechnology. 2018, 16(1), 71.
Sartore-Bianchi A, Bencardino K, Di Nicolantonio F, Pozzi F, Funaioli C, et al. Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer. Targeted Oncology. 2010, 5(1), 19-28.
Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, et al. Engineering Precision Nanoparticles for Drug Delivery. Nature Reviews Drug Discovery. 2020, 20(2), 101-124.
Yardley DA. Nab-Paclitaxel Mechanism of Action and Efficacy in Breast Cancer. Breast Cancer Research and Treatment. 2013, 138(1), 3-7.
Toussaint K, Yang Y. Liposomal cisplatin (Lipoplatin): Formulation, Clinical Studies and Perspectives. Journal of Nanomedicine & Nanotechnology. 2021, 12(2), 521-530.
Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, et al. Nanoliposomal Irinotecan with Fluorouracil and Folinic Acid in Metastatic Pancreatic Cancer (NAPOLI-1): A Global, Randomised, Open-Label, Phase 3 Trial. The Lancet. 2016, 387(10018), 545-557.
Quinn JA, Jiang Z, Grim A. Phase II Trial of Onivyde (Liposomal Irinotecan) for Refractory Colorectal Cancer. Clinical Cancer Research. 2013, 19(23), 6596-6603.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Journal of Cancer Biomoleculars and Therapeutics
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
